PCM
LXEO icon

Prelude Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Prelude Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
+22,500
New +$122K 0.01% 1107
2024
Q4 		– Sell
-30,725
Closed -$278K – 1403
2024
Q3 		$278K Buy
+30,725
New +$366K 0.02% 902

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Prelude Capital Management's LXEO Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 22,500 shares worth $105K. The stake represents 0.01% of the portfolio and ranks #1107 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in LXEO as recently as Q3 2024.

Prelude Capital Management first reported a position in LXEO in Q3 2024 and has held it in 2 quarters since. The position peaked at $278K in Q3 2024. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Prelude Capital Management held 22,500 shares of Lexeo Therapeutics worth $105K as of Q2 2026.
  • Lexeo Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • Lexeo Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1107 holding.
  • Prelude Capital Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • Prelude Capital Management's Lexeo Therapeutics position peaked at $278K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.